Solid Biosciences Inc SLDB:NASDAQ

RT Quote | Last NASDAQ LS, VOL From CTA | USD
Last | 4:00 PM EDT
8.77quote price arrow down-0.34 (-3.73%)
Volume
137,718
52 week range
1.81 - 15.05
Loading...
  • Open9.03
  • Day High9.28
  • Day Low8.54
  • Prev Close9.11
  • 52 Week High15.05
  • 52 Week High Date03/28/24
  • 52 Week Low1.81
  • 52 Week Low Date10/30/23

Key Stats

  • Market Cap331.128M
  • Shares Out37.76M
  • 10 Day Average Volume0.17M
  • Dividend-
  • Dividend Yield-
  • Beta2.02
  • YTD % Change42.83

KEY STATS

  • Open9.03
  • Day High9.28
  • Day Low8.54
  • Prev Close9.11
  • 52 Week High15.05
  • 52 Week High Date03/28/24
  • 52 Week Low1.81
  • 52 Week Low Date10/30/23
  • Market Cap331.128M
  • Shares Out37.76M
  • 10 Day Average Volume0.17M
  • Dividend-
  • Dividend Yield-
  • Beta2.02
  • YTD % Change42.83

RATIOS/PROFITABILITY

  • EPS (TTM)-4.84
  • P/E (TTM)-1.81
  • Fwd P/E (NTM)-3.30
  • EBITDA (TTM)-101.36M
  • ROE (TTM)-56.79%
  • Revenue (TTM)-
  • Gross Margin (TTM)-
  • Net Margin (TTM)-1,470.63%
  • Debt To Equity (MRQ)1.35%

EVENTS

  • Earnings Date05/09/2024(est)
  • Ex Div Date-
  • Div Amount-
  • Split Date-
  • Split Factor-

Latest On Solid Biosciences Inc

 

Profile

MORE
Solid Biosciences Inc. is a life sciences company developing precision genetic medicines for neuromuscular and cardiac diseases. The Company is focused on advancing a portfolio of gene therapy candidates including SGT-003 for the treatment of Duchenne muscular dystrophy, SGT-501 for the treatment of catecholaminergic polymorphic ventricular tachycardia, AVB-401 for the treatment of BAG3-mediated dilated cardiomyopathy, and additional assets for the treatment of fatal cardiac...
Ian Smith CPA
Executive Chairman of the Board
Alexander Cumbo
President, Chief Executive Officer, Director
Kevin Tan
Chief Financial Officer, Treasurer
Paul Herzich
Chief Technology Officer
Address
500 RUTHERFORD AVENUE, 3RD FLOOR
Charlestown, MA
02129
United States